BridgeBio Pharma, Inc.
Every calculator, already run for BBIO
Open the full toolkit →You have the numbers on BBIO. Get the argument.
A written report on which of these readings actually decide the outcome for BridgeBio Pharma, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
22 analysts covering BBIOAnalyst Price Target Disagreement for BridgeBio Pharma, Inc.
Wall Street's bull case implies +110% from the current price; the bear case implies +8%. A 102% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for BBIO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops…
BBIO — frequently asked
Is BBIO a buy right now?
Wall Street's consensus rating on BridgeBio Pharma, Inc. is Strong Buy across 22 analysts, with a mean price target of $106.85 (+44% vs. the current $74.29). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for BridgeBio Pharma, Inc.?
Analysts covering BridgeBio Pharma, Inc. (BBIO) range from a bear-case target of $80.00 to a bull-case high of $156.00, with a mean consensus target of $106.85 across 20 analysts. The spread of $76.00 (102% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare BridgeBio Pharma, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For BridgeBio Pharma, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BBIO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on BridgeBio Pharma, Inc., in minutes. 3 free reports included with every account — no credit card required.